0

Close
 
Upcoming Allied Market Research
2023
Allergy Immunotherapy Market

Allergy Immunotherapy Market: Global Opportunity Analysis and Industry Forecast 2019-2026 Market

LS : Medical Devices & Supplies
Report Code: A10241
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Allergy Immunotherapy Market

Request Now !

Allergy immunotherapy is an adaptive therapy for diseases which is effectual during the treatment of allergic conjunctivitis, peanuts allergy, allergic asthma, cat allergy, stinging insect hypersensitivity, etc.. Immunotherapy is a treatment for prevention of various allergic reactions like house dust mites, grass pollens, and bee venom. Immunotherapy is increasing the dosages of the substance in which the person is allergic over some time. Increase in the allergens causes the immune system to lower the sensitivity to the substance by causing the production of an antibody that will reduce the symptoms of allergy when the person comes in contact with the substance in the future. Immunotherapy is also used to reduce the inflammation of diseases like rhinitis and asthma.

Allergy Immunotherapy Market

Before initiating the treatment, the immunology physician and patient identify all the trigger factors for allergy symptoms. Various skin and blood tests are performed for the confirmation of specific antigens to which the person has antibodies. Immunotherapy is usually commended only and only if the person seems to be selectively sensitive to several allergens.

COVID-19 scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

Owing to such factors, COVID 19 is expected to have a significant impact on the Allergy immunotherapy market.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

After the launches of various new sublingual immuno-therapies in developing countries and the influence of many major players in the allergen immunotherapy market, an increase in an unmet need for novel targeted drugs which can be used to treat the disease conditions are the major factors driving the market. Sublingual allergy immunotherapy has now been clinically proven a more efficient treatment with lesser side effects as compared to alternatives available in the market currently. There is also a change observed in demographics concerning population and macroeconomic climate are other factors driving towards allergy immunotherapy market. 

On the other hand, allergy immunotherapy drugs can also cause severe allergic reactions that may be fatal in some cases, and due to the limited availability of therapy in few countries it is a challenge for the allergy immunotherapy market. Additionally, less awareness about immunotherapy is limiting the growth of the sublingual allergy immunotherapy market. Also there is a lack of skilled professionals and high technological cost which is hampering the market’s development.

New product launches to flourish the market:

In January 2017, ALK Abello A/S acquired of Allergy Laboratory of Oklahoma Inc. and Crystal Labs LLC.

In October 2017, DBV Technologies entered intoR and D agreement with Stallergenes S.A. for birch allergy treatment.

In January 2017, Merck acquired BioControl which helped them strengthen their capabilities in food safety testing.

Surge in usage in hospital applications:

Improving and significantly growing healthcare infrastructure, and growing awareness about allergy immunotherapy and there is also a high prevalence of nasal allergies been observed in the recent year which will increase the demand for allergy treatment market.

Key benefits of the report:

  • This study presents the analytical depiction of the global Allergy immunotherapy industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Allergy immunotherapy market share.
  • The current market is quantitatively analyzed to highlight the global Allergy immunotherapy market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global Allergy immunotherapy market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Allergy immunotherapy Market research report:

  • What are the leading market players active in the Allergy immunotherapy market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

 Allergy Immunotherapy Market: Global Opportunity Analysis and Industry Forecast 2019–2026 Report Highlights

Aspects Details
By Allergy Type
  • Allergic Rhinitis
  • Allergic Asthma
  • Peanut Allergy
  • Cat Allergy
  • Others
By   Treatment
  • Sublingual Immunotherapy
  • Subcutaneous Immunotherapy (SCIT)
  • Specific Immunotherapy (SIT)
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Stallergenes Greer, Letiand, HolisterStier, Allergy Therapeutic, WOLWpharma, ALK Abello A/S, Circassia, DBV Technologies, Merck KGaA (Allergopharma), HAL Allergy Group
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: ALLERGY IMMUNOTHERAPY MARKET, BY ALLERGY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Allergy Type

    • 4.2. Allergic Rhinitis

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Allergic Asthma

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Peanut Allergy

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Cat Allergy

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: ALLERGY IMMUNOTHERAPY MARKET, BY   TREATMENT

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By   Treatment

    • 5.2. Sublingual Immunotherapy

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Subcutaneous Immunotherapy (SCIT)

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Specific Immunotherapy (SIT)

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospital Pharmacy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Retail Pharmacy

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Online Pharmacy

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: ALLERGY IMMUNOTHERAPY MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Allergy Type

      • 7.2.3. Market Size and Forecast, By   Treatment

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Allergy Immunotherapy Market

        • 7.2.6.1. Market Size and Forecast, By Allergy Type
        • 7.2.6.2. Market Size and Forecast, By   Treatment
        • 7.2.6.3. Market Size and Forecast, By Distribution Channel

      • 7.2.7. Canada Allergy Immunotherapy Market

        • 7.2.7.1. Market Size and Forecast, By Allergy Type
        • 7.2.7.2. Market Size and Forecast, By   Treatment
        • 7.2.7.3. Market Size and Forecast, By Distribution Channel

      • 7.2.8. Mexico Allergy Immunotherapy Market

        • 7.2.8.1. Market Size and Forecast, By Allergy Type
        • 7.2.8.2. Market Size and Forecast, By   Treatment
        • 7.2.8.3. Market Size and Forecast, By Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Allergy Type

      • 7.3.3. Market Size and Forecast, By   Treatment

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Allergy Immunotherapy Market

        • 7.3.6.1. Market Size and Forecast, By Allergy Type
        • 7.3.6.2. Market Size and Forecast, By   Treatment
        • 7.3.6.3. Market Size and Forecast, By Distribution Channel

      • 7.3.7. Germany Allergy Immunotherapy Market

        • 7.3.7.1. Market Size and Forecast, By Allergy Type
        • 7.3.7.2. Market Size and Forecast, By   Treatment
        • 7.3.7.3. Market Size and Forecast, By Distribution Channel

      • 7.3.8. Italy Allergy Immunotherapy Market

        • 7.3.8.1. Market Size and Forecast, By Allergy Type
        • 7.3.8.2. Market Size and Forecast, By   Treatment
        • 7.3.8.3. Market Size and Forecast, By Distribution Channel

      • 7.3.9. Spain Allergy Immunotherapy Market

        • 7.3.9.1. Market Size and Forecast, By Allergy Type
        • 7.3.9.2. Market Size and Forecast, By   Treatment
        • 7.3.9.3. Market Size and Forecast, By Distribution Channel

      • 7.3.10. UK Allergy Immunotherapy Market

        • 7.3.10.1. Market Size and Forecast, By Allergy Type
        • 7.3.10.2. Market Size and Forecast, By   Treatment
        • 7.3.10.3. Market Size and Forecast, By Distribution Channel

      • 7.3.11. Russia Allergy Immunotherapy Market

        • 7.3.11.1. Market Size and Forecast, By Allergy Type
        • 7.3.11.2. Market Size and Forecast, By   Treatment
        • 7.3.11.3. Market Size and Forecast, By Distribution Channel

      • 7.3.12. Rest Of Europe Allergy Immunotherapy Market

        • 7.3.12.1. Market Size and Forecast, By Allergy Type
        • 7.3.12.2. Market Size and Forecast, By   Treatment
        • 7.3.12.3. Market Size and Forecast, By Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Allergy Type

      • 7.4.3. Market Size and Forecast, By   Treatment

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Allergy Immunotherapy Market

        • 7.4.6.1. Market Size and Forecast, By Allergy Type
        • 7.4.6.2. Market Size and Forecast, By   Treatment
        • 7.4.6.3. Market Size and Forecast, By Distribution Channel

      • 7.4.7. Japan Allergy Immunotherapy Market

        • 7.4.7.1. Market Size and Forecast, By Allergy Type
        • 7.4.7.2. Market Size and Forecast, By   Treatment
        • 7.4.7.3. Market Size and Forecast, By Distribution Channel

      • 7.4.8. India Allergy Immunotherapy Market

        • 7.4.8.1. Market Size and Forecast, By Allergy Type
        • 7.4.8.2. Market Size and Forecast, By   Treatment
        • 7.4.8.3. Market Size and Forecast, By Distribution Channel

      • 7.4.9. South Korea Allergy Immunotherapy Market

        • 7.4.9.1. Market Size and Forecast, By Allergy Type
        • 7.4.9.2. Market Size and Forecast, By   Treatment
        • 7.4.9.3. Market Size and Forecast, By Distribution Channel

      • 7.4.10. Australia Allergy Immunotherapy Market

        • 7.4.10.1. Market Size and Forecast, By Allergy Type
        • 7.4.10.2. Market Size and Forecast, By   Treatment
        • 7.4.10.3. Market Size and Forecast, By Distribution Channel

      • 7.4.11. Thailand Allergy Immunotherapy Market

        • 7.4.11.1. Market Size and Forecast, By Allergy Type
        • 7.4.11.2. Market Size and Forecast, By   Treatment
        • 7.4.11.3. Market Size and Forecast, By Distribution Channel

      • 7.4.12. Malaysia Allergy Immunotherapy Market

        • 7.4.12.1. Market Size and Forecast, By Allergy Type
        • 7.4.12.2. Market Size and Forecast, By   Treatment
        • 7.4.12.3. Market Size and Forecast, By Distribution Channel

      • 7.4.13. Indonesia Allergy Immunotherapy Market

        • 7.4.13.1. Market Size and Forecast, By Allergy Type
        • 7.4.13.2. Market Size and Forecast, By   Treatment
        • 7.4.13.3. Market Size and Forecast, By Distribution Channel

      • 7.4.14. Rest of Asia Pacific Allergy Immunotherapy Market

        • 7.4.14.1. Market Size and Forecast, By Allergy Type
        • 7.4.14.2. Market Size and Forecast, By   Treatment
        • 7.4.14.3. Market Size and Forecast, By Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Allergy Type

      • 7.5.3. Market Size and Forecast, By   Treatment

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Allergy Immunotherapy Market

        • 7.5.6.1. Market Size and Forecast, By Allergy Type
        • 7.5.6.2. Market Size and Forecast, By   Treatment
        • 7.5.6.3. Market Size and Forecast, By Distribution Channel

      • 7.5.7. South Africa Allergy Immunotherapy Market

        • 7.5.7.1. Market Size and Forecast, By Allergy Type
        • 7.5.7.2. Market Size and Forecast, By   Treatment
        • 7.5.7.3. Market Size and Forecast, By Distribution Channel

      • 7.5.8. Saudi Arabia Allergy Immunotherapy Market

        • 7.5.8.1. Market Size and Forecast, By Allergy Type
        • 7.5.8.2. Market Size and Forecast, By   Treatment
        • 7.5.8.3. Market Size and Forecast, By Distribution Channel

      • 7.5.9. UAE Allergy Immunotherapy Market

        • 7.5.9.1. Market Size and Forecast, By Allergy Type
        • 7.5.9.2. Market Size and Forecast, By   Treatment
        • 7.5.9.3. Market Size and Forecast, By Distribution Channel

      • 7.5.10. Argentina Allergy Immunotherapy Market

        • 7.5.10.1. Market Size and Forecast, By Allergy Type
        • 7.5.10.2. Market Size and Forecast, By   Treatment
        • 7.5.10.3. Market Size and Forecast, By Distribution Channel

      • 7.5.11. Rest of LAMEA Allergy Immunotherapy Market

        • 7.5.11.1. Market Size and Forecast, By Allergy Type
        • 7.5.11.2. Market Size and Forecast, By   Treatment
        • 7.5.11.3. Market Size and Forecast, By Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. ALK Abello A/S

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Allergy Therapeutic

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Circassia

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. DBV Technologies

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Stallergenes Greer

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Merck KGaA (Allergopharma)

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. WOLWpharma

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. HolisterStier

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Letiand

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. HAL Allergy Group

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR ALLERGIC RHINITIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR ALLERGIC ASTHMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR PEANUT ALLERGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR CAT ALLERGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR SUBLINGUAL IMMUNOTHERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR SUBCUTANEOUS IMMUNOTHERAPY (SCIT), BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR SPECIFIC IMMUNOTHERAPY (SIT), BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL ALLERGY IMMUNOTHERAPY MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA ALLERGY IMMUNOTHERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. U.S. ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 21. U.S. ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 22. U.S. ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. CANADA ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. CANADA ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 25. CANADA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE ALLERGY IMMUNOTHERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. ITALY ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 40. ITALY ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 41. ITALY ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. UK ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 46. UK ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 47. UK ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. RUSSIA ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. RUSSIA ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 50. RUSSIA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 53. REST OF EUROPE ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. CHINA ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 59. CHINA ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 60. CHINA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. JAPAN ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 62. JAPAN ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 63. JAPAN ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. INDIA ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 65. INDIA ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 66. INDIA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. AUSTRALIA ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 71. AUSTRALIA ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 72. AUSTRALIA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. THAILAND ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 74. THAILAND ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 75. THAILAND ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 76. MALAYSIA ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 77. MALAYSIA ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 78. MALAYSIA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. INDONESIA ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 80. INDONESIA ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 81. INDONESIA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 85. LAMEA ALLERGY IMMUNOTHERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 87. LAMEA ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 88. LAMEA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 89. BRAZIL ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 90. BRAZIL ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 91. BRAZIL ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH AFRICA ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 95. SAUDI ARABIA ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 96. SAUDI ARABIA ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 97. SAUDI ARABIA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 98. UAE ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 99. UAE ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 100. UAE ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 101. ARGENTINA ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 102. ARGENTINA ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 103. ARGENTINA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 104. REST OF LAMEA ALLERGY IMMUNOTHERAPY, BY ALLERGY TYPE, 2022-2032 ($MILLION)
  • TABLE 105. REST OF LAMEA ALLERGY IMMUNOTHERAPY, BY   TREATMENT, 2022-2032 ($MILLION)
  • TABLE 106. REST OF LAMEA ALLERGY IMMUNOTHERAPY, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 107. ALK ABELLO A/S: KEY EXECUTIVES
  • TABLE 108. ALK ABELLO A/S: COMPANY SNAPSHOT
  • TABLE 109. ALK ABELLO A/S: OPERATING SEGMENTS
  • TABLE 110. ALK ABELLO A/S: PRODUCT PORTFOLIO
  • TABLE 111. ALK ABELLO A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. ALLERGY THERAPEUTIC: KEY EXECUTIVES
  • TABLE 113. ALLERGY THERAPEUTIC: COMPANY SNAPSHOT
  • TABLE 114. ALLERGY THERAPEUTIC: OPERATING SEGMENTS
  • TABLE 115. ALLERGY THERAPEUTIC: PRODUCT PORTFOLIO
  • TABLE 116. ALLERGY THERAPEUTIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. CIRCASSIA: KEY EXECUTIVES
  • TABLE 118. CIRCASSIA: COMPANY SNAPSHOT
  • TABLE 119. CIRCASSIA: OPERATING SEGMENTS
  • TABLE 120. CIRCASSIA: PRODUCT PORTFOLIO
  • TABLE 121. CIRCASSIA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. DBV TECHNOLOGIES: KEY EXECUTIVES
  • TABLE 123. DBV TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 124. DBV TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 125. DBV TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 126. DBV TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. STALLERGENES GREER: KEY EXECUTIVES
  • TABLE 128. STALLERGENES GREER: COMPANY SNAPSHOT
  • TABLE 129. STALLERGENES GREER: OPERATING SEGMENTS
  • TABLE 130. STALLERGENES GREER: PRODUCT PORTFOLIO
  • TABLE 131. STALLERGENES GREER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. MERCK KGAA (ALLERGOPHARMA): KEY EXECUTIVES
  • TABLE 133. MERCK KGAA (ALLERGOPHARMA): COMPANY SNAPSHOT
  • TABLE 134. MERCK KGAA (ALLERGOPHARMA): OPERATING SEGMENTS
  • TABLE 135. MERCK KGAA (ALLERGOPHARMA): PRODUCT PORTFOLIO
  • TABLE 136. MERCK KGAA (ALLERGOPHARMA): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. WOLWPHARMA: KEY EXECUTIVES
  • TABLE 138. WOLWPHARMA: COMPANY SNAPSHOT
  • TABLE 139. WOLWPHARMA: OPERATING SEGMENTS
  • TABLE 140. WOLWPHARMA: PRODUCT PORTFOLIO
  • TABLE 141. WOLWPHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. HOLISTERSTIER: KEY EXECUTIVES
  • TABLE 143. HOLISTERSTIER: COMPANY SNAPSHOT
  • TABLE 144. HOLISTERSTIER: OPERATING SEGMENTS
  • TABLE 145. HOLISTERSTIER: PRODUCT PORTFOLIO
  • TABLE 146. HOLISTERSTIER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. LETIAND: KEY EXECUTIVES
  • TABLE 148. LETIAND: COMPANY SNAPSHOT
  • TABLE 149. LETIAND: OPERATING SEGMENTS
  • TABLE 150. LETIAND: PRODUCT PORTFOLIO
  • TABLE 151. LETIAND: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. HAL ALLERGY GROUP: KEY EXECUTIVES
  • TABLE 153. HAL ALLERGY GROUP: COMPANY SNAPSHOT
  • TABLE 154. HAL ALLERGY GROUP: OPERATING SEGMENTS
  • TABLE 155. HAL ALLERGY GROUP: PRODUCT PORTFOLIO
  • TABLE 156. HAL ALLERGY GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ALLERGY IMMUNOTHERAPY MARKET
  • FIGURE 3. SEGMENTATION ALLERGY IMMUNOTHERAPY MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ALLERGY IMMUNOTHERAPY MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALALLERGY IMMUNOTHERAPY MARKET
  • FIGURE 11. ALLERGY IMMUNOTHERAPY MARKET SEGMENTATION, BY BY ALLERGY TYPE
  • FIGURE 12. ALLERGY IMMUNOTHERAPY MARKET FOR ALLERGIC RHINITIS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. ALLERGY IMMUNOTHERAPY MARKET FOR ALLERGIC ASTHMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. ALLERGY IMMUNOTHERAPY MARKET FOR PEANUT ALLERGY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. ALLERGY IMMUNOTHERAPY MARKET FOR CAT ALLERGY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. ALLERGY IMMUNOTHERAPY MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. ALLERGY IMMUNOTHERAPY MARKET SEGMENTATION, BY BY   TREATMENT
  • FIGURE 18. ALLERGY IMMUNOTHERAPY MARKET FOR SUBLINGUAL IMMUNOTHERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. ALLERGY IMMUNOTHERAPY MARKET FOR SUBCUTANEOUS IMMUNOTHERAPY (SCIT), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. ALLERGY IMMUNOTHERAPY MARKET FOR SPECIFIC IMMUNOTHERAPY (SIT), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. ALLERGY IMMUNOTHERAPY MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 22. ALLERGY IMMUNOTHERAPY MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. ALLERGY IMMUNOTHERAPY MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. ALLERGY IMMUNOTHERAPY MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: ALLERGY IMMUNOTHERAPY MARKET
  • FIGURE 31. Top player positioning, 2022
  • FIGURE 32. ALK ABELLO A/S: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. ALK ABELLO A/S: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. ALK ABELLO A/S: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. ALLERGY THERAPEUTIC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. ALLERGY THERAPEUTIC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. ALLERGY THERAPEUTIC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. CIRCASSIA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. CIRCASSIA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. CIRCASSIA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. DBV TECHNOLOGIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. DBV TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. DBV TECHNOLOGIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. STALLERGENES GREER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. STALLERGENES GREER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. STALLERGENES GREER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. MERCK KGAA (ALLERGOPHARMA): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. MERCK KGAA (ALLERGOPHARMA): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. MERCK KGAA (ALLERGOPHARMA): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. WOLWPHARMA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. WOLWPHARMA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. WOLWPHARMA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. HOLISTERSTIER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. HOLISTERSTIER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. HOLISTERSTIER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. LETIAND: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. LETIAND: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. LETIAND: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. HAL ALLERGY GROUP: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. HAL ALLERGY GROUP: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. HAL ALLERGY GROUP: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Allergy Immunotherapy Market

Start reading.
This Report and over 67,540+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers